A new daily pill for chronic hives when antihistamines are not enough
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new daily pill called TLL-018 (a JAK inhibitor) for people with chronic hives that still cause symptoms despite taking antihistamines. It aims to see how fast it relieves itching and hives.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have had chronic spontaneous urticaria (hives that come and go for at least 6 weeks without a clear trigger) for at least 6 months.
- Despite taking a daily antihistamine (like cetirizine or loratadine) for at least 6 weeks, you still have itching and hives.
- You must be willing to keep taking your usual antihistamine throughout the trial.
- You cannot have taken certain other experimental or biologic drugs recently, including omalizumab (Xolair) at any time.
- You must not have certain health issues like active infections, recent blood clots, or abnormal lab results (e.g., low blood counts, high liver enzymes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication (TLL-018) for people with chronic hives that don't fully go away with standard antihistamines. It aims to see if the drug reduces itching and hives better than placebo.
This study tests an investigational pill called THB335 for adults whose hives (itchy welts) keep appearing despite taking antihistamines. The goal is to see if this treatment can reduce itching and hives and improve quality of life.
This trial tests a new oral medication for chronic spontaneous urticaria (chronic hives). It is a placebo-controlled study, meaning some participants will get the new drug and some will get a placebo (a pill with no active ingredient). The goal is to see if the new drug is safe and how well it works, possibly providing a new treatment option for those whose hives are not controlled by current antihistamines.
This trial tests a new injection (CM512) for people with chronic spontaneous urticaria, also known as chronic hives. If you have had itchy hives for at least 6 weeks despite taking regular antihistamines, this study may help find a new treatment option.
This trial tests an experimental drug called ICP-332 for people with chronic spontaneous urticaria (long-term hives) that is not well controlled by standard antihistamines. The goal is to see if the drug is safe and effective at reducing hives.
This study tests whether adding a bacterial extract called OM-85 to your usual antihistamine helps control chronic hives better than antihistamines alone. It is an observational study, meaning the treatment is decided by your doctor, not assigned randomly.
Hear when a new Chronic Spontaneous Urticaria (CSU) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.